JAMA dermatology

Guide to Using GLP-1 Receptor Agonists for Treating Psoriasis

Updated

Abstract

GLP-1 receptor agonists may reduce Psoriasis Area and Severity Index (PASI) scores by approximately 40% to 80% in patients with obesity or type 2 diabetes.

  • Emerging evidence suggests GLP-1 receptor agonists could improve psoriatic skin disease through immune modulation.
  • Semaglutide and liraglutide have been linked to reductions in C-reactive protein, interleukin-6, lipids, and visceral fat.
  • Improvements in PASI scores have correlated with decreases in superficial fat and specific immune cell density.
  • GLP-1 receptor agonists appear to combine safely with existing psoriasis treatments such as methotrexate and biologics.
  • Adverse effects are primarily transient gastrointestinal symptoms, with rare occurrences of pancreatitis and gallbladder issues.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free